NMC
NEA Management Company Portfolio holdings
AUM
$1.33B
This Quarter Return
+20.54%
1 Year Return
+85.82%
3 Year Return
+531.37%
5 Year Return
+304.32%
10 Year Return
+4,927.96%
AUM
$2.51B
AUM Growth
+$2.51B
(+13%)
Cap. Flow
+$31M
Cap. Flow
% of AUM
1.23%
Top 10 Holdings %
Top 10 Hldgs %
85.06%
Holding
41
New
2
Increased
5
Reduced
4
Closed
2
Top Buys
| 1 |
CRISPR Therapeutics
CRSP
|
$65.3M |
| 2 |
RARX
Ra Pharmaceuticals, Inc. Common Stock
RARX
|
$53.1M |
| 3 |
AKAO
Achaogen, Inc.
AKAO
|
$6.51M |
| 4 |
SBBP
Strongbridge Biopharma plc.
SBBP
|
$4.8M |
| 5 |
TCON
TRACON Pharmaceuticals, Inc. Common Stock
TCON
|
$4.26M |
Top Sells
| 1 |
CASC
Cascadian Therapeutics, Inc.
CASC
|
$38.6M |
| 2 |
LOXO
Loxo Oncology, Inc
LOXO
|
$33.8M |
| 3 |
NVRO
NEVRO CORP.
NVRO
|
$21.9M |
| 4 |
ROKA
Sorrento Tech, Inc. Common Stock
ROKA
|
$9.87M |
| 5 |
XCOM
XTERA COMMUNICATIONS INC COM STK (DE)
XCOM
|
$2M |
Sector Composition
| 1 | Healthcare | 84.52% |
| 2 | Technology | 4.04% |
| 3 | Communication Services | 2.65% |
| 4 | Consumer Discretionary | 1.11% |
